Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04339452 · ClinicalTrials.gov registry record
Impella Supported OPCABG
A clinical trial of Ischemic Cardiomyopathy, sponsored by Lucian Archambault Durham III.
- Active
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT04339452 is a study of Ischemic Cardiomyopathy that is active but no longer recruiting, run by Lucian Archambault Durham III. The registered enrollment target is 30 participants, below the 376-participant average among 10 other Ischemic Cardiomyopathy trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04339452, a study of Ischemic Cardiomyopathy, is active but no longer recruiting, sponsored by Lucian Archambault Durham III.
- ACTIVE NOT RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The present study introduces a novel approach to coronary revascularization through the use of a short term minimally-invasive left ventricular assist device (LVAD) to minimize myocardial injury and eliminate low output state during the perioperative period
Conditions Studied
Interventions
- DEVICE Impella 5.5 with SmartAssist Supported OPCABG
Study Locations (1)
Wisconsin
- The Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-05-11 |
| Est. Completion | 2026-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04339452
The ClinicalTrials.gov registry entry for NCT04339452 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 10 other Ischemic Cardiomyopathy trials with a reported enrollment target (92% lower). The listed sponsor is Lucian Archambault Durham III, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ischemic Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which Impella 5.5 with SmartAssist Supported OPCABG is the first listed.
NCT04339452 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04339452 about?
NCT04339452 is a clinical study titled "Impella Supported OPCABG". The present study introduces a novel approach to coronary revascularization through the use of a short term minimally-invasive left ventricular assist device (LVAD) to minimize myocardial injury and eliminate low output state during the perioperative period
What is the current status of trial NCT04339452?
This trial is currently active not recruiting. The enrollment target is 30 participants. The study started on 2022-05-11. Estimated completion is 2026-03.
What conditions does trial NCT04339452 study?
This clinical trial studies the following conditions: Ischemic Cardiomyopathy.
What interventions are being tested in trial NCT04339452?
The interventions under investigation include: Impella 5.5 with SmartAssist Supported OPCABG (DEVICE).
Who is sponsoring clinical trial NCT04339452?
This trial is sponsored by Lucian Archambault Durham III, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04339452 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Left Ventricular Structural Predictors of Sudden Cardiac Death
RECRUITING
-
Implantable Cardioverter Defibrillator (ICD Registry)
RECRUITING
-
Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy
RECRUITING · NA
-
Phenotypic Classification of FMR With CMR
RECRUITING
-
Venous Ethanol for Ventricular Tachycardia
RECRUITING · Phase 2
-
Assessment of Combined CCM and ICD Device in HFrEF
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.